Genmab ( (GMAB) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Genmab’s stock took a hit after Johnson & Johnson opted not to license HexaBody-CD38, despite its promising trial results. Genmab decided to halt its development due to market considerations and prioritizing other projects. This decision doesn’t affect their 2025 financial outlook as they focus on other promising assets. Analysts have kept a Hold rating, indicating a cautious approach.
More about Genmab
YTD Price Performance: 14.95%
Average Trading Volume: 1,328,004
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.32B
For further insights into GMAB stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.
Questions or Comments about the article? Write to editor@tipranks.com